Group 1: Company Performance - The company's Xigua Frost series suffered significant losses during the pandemic, while the Sanjin Pian series maintained stable sales, becoming the main driver of the company's performance [1] - In 2022, the company experienced a recovery in Xigua Frost sales after the lifting of pandemic controls, with inventory replenishment completed by February 2023 [1] Group 2: Product Composition and Market Strategy - The company has a product composition of approximately 70% OTC (over-the-counter) drugs and 30% prescription drugs, with Sanjin Pian having a slightly higher hospital usage ratio compared to Xigua Frost [1] - The company views centralized procurement of traditional Chinese medicine as an opportunity rather than a challenge, especially for its unique products like Sanjin Pian, which are included in essential drug lists and have limited price reduction potential [1] Group 3: Research and Development - Baoshuan Bio is currently facing losses in R&D, but plans to continue investment in R&D and explore other business models, including financing and partnerships, without losing control [2] - The company expects to obtain 1-2 new clinical approvals in the current year, as part of its strategy to integrate resources and prepare for potential IPO [2]

Group 1: Company Strategy - The company's overall strategy focuses on traditional Chinese medicine as the core, with biopharmaceuticals and health industries as wings [1] - The traditional Chinese medicine segment includes over 40 proprietary products, categorized into first-line (e.g., Sanjin Pian, Xigua Shuang), second-line (e.g., Xuanvining, Naomaithai), and third-line products [1] Group 2: Revenue Composition - The majority of sales revenue comes from traditional Chinese medicine, with a smaller portion from chemical drugs and health products [1] - First-line products, such as the Sanjin Pian series and Xigua Shuang series, contribute significantly to revenue, while many third-line products are still in the market introduction phase [1] Group 3: OTC and Prescription Drug Ratio - The company has a ratio of approximately 70% OTC to 30% prescription drugs, with specific products like the Xigua Shuang series maintaining a 60/40 ratio [2] - The company views centralized procurement of traditional Chinese medicine as an opportunity rather than a challenge, as many products are unique and listed in essential drug directories [2] Group 4: R&D and Future Prospects - Baoshuan Biotech currently has 8 products with clinical approval and expects to obtain 1-2 new clinical approvals this year [2] - Baifang Biotech, positioned as the production base for biopharmaceuticals, aims to achieve breakeven this year while preparing for FDA certification [2]

Group 1: Company Overview and Strategic Goals - Guilin Sanjin aims to modernize traditional Chinese medicine through innovation, focusing on modern Chinese medicine preparations as its core industry [2] - The company plans to expand its vertical industry chain and explore fields such as biopharmaceuticals, chemical drugs, and health products to enhance its professional management level [3] Group 2: Health Industry Development - After integrating Guilin Sanjin Watermelon Frost Ecological Company into its listing system, the company will focus on research and development in the health sector, leveraging its market and brand advantages in throat-related traditional Chinese medicine [3] - The company intends to develop oral care products like Watermelon Frost toothpaste to extend its product line and optimize its business structure [3] Group 3: Biopharmaceuticals and Future Plans - Baoshuan Biotech, established in 2005, specializes in the research and production of biopharmaceuticals, with several biosimilar drugs under development targeting malignant tumors [4] - The company aims to submit 1-2 products for clinical trials within the year [4] Group 4: Expansion and Acquisition Strategy - To maintain its leading position in the traditional Chinese medicine industry, Guilin Sanjin is actively seeking strategic acquisitions of quality domestic pharmaceutical companies [4] - The company plans to capitalize on the upcoming deadline for new GMP certification to acquire pharmaceutical enterprises with strong product and resource advantages [4]

附件二、投资者关系活动记录表 证券代码： 002275 证券简称：桂林三金 桂林三金药业股份有限公司投资者关系活动记录表 编号：2015006 | --- | --- | --- | |-------------------------|----------------------------------|--------------------------------------------------------| | | | | | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 建信基金管理公司 邵卓 陶灿 孙晟 吴尚伟 | | | | | | 时间 | 2015 年 06 月 19 日 | | | 地点 | 桂林三金药业股份有限公司 | | | 上市公司接待人 | 董事常务副总裁兼董事会秘书：邹洵 | | | 员 | 投资者关系管理专员： ...

附件二、投资者关系活动记录表 证券代码： 002275 证券简称：桂林三金 桂林三金药业股份有限公司投资者关系活动记录表 编号：2016001 | --- | --- | --- | |----------------|----------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 华宝信托有限责任公司 俞向兵 西南证券 周平 | | 人员姓名 | | 国信证券广东南海分公司 余思颖 广证恒生 陈顺 | | 时间 | 2016 年 03 月 22 日 | | | 地点 | 桂林三金药业股份有限公司会议室 | | | 上市公司接待人 | 董事常务副总裁兼董事会秘书：邹洵 | | | 员 | ...

附件二、投资者关系活动记录表 证券代码： 002275 证券简称：桂林三金 桂林三金药业股份有限公司投资者关系活动记录表 编号：2016002 | --- | --- | --- | |----------------|----------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 深圳兆丰禾投资管理有限公司 陈召洪 李权兵 | | 人员姓名 | | 广州瑞民投资管理有限公司 匡立春 黄晓坤 | | | 广证恒生 陈顺 | | | 时间 | 2016 年 05 月 25 日 | | | 地点 | 桂林三金药业股份有限公司会议室 | | | 上市公司接待人 | 董事常务副总裁兼董事会秘书： ...

附件二、投资者关系活动记录表 证券代码： 002275 证券简称：桂林三金 编号：2016003 | --- | --- | --- | |----------------|----------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 广发证券 李士好 银河证券 李志荣 | | | 人员姓名 | 广东锦洋投资有限公司 梁华滨 | | | | | 珠江西江产业投资基金管理有限公司 何锋 熊祥云 | | 时间 | 2016 年 11 月 18 | 日 | | 地点 | 桂林三金药业股份有限公司会议室 | | | 上市公司接待人 | 董事常务副总裁兼董事会秘书：邹洵 | | | 员 | 投资者关 ...

附件二、投资者关系活动记录表 证券代码： 002275 证券简称：桂林三金 桂林三金药业股份有限公司投资者关系活动记录表 编号：2017001 | --- | --- | --- | |----------------|----------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 广证恒生 唐爱金 | | | 人员姓名 | | | | 时间 | 2017 年 1 月 12 日 | | | 地点 | 桂林三金药业股份有限公司会议室 | | | 上市公司接待人 | 董事常务副总裁兼董事会秘书：邹洵 | | | 员 | 投资者关系管理专员：邓强 | | | 投资者关系活动 | 一、公司的长期的规 ...